Altimmune
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $5 | $5 | $5 | $37 |
Gross Profit | 5 | -56 | -102 | -1,853 |
EBITDA | -24,767 | -24,578 | -24,287 | -29,749 |
EBIT | -24,804 | -24,639 | -24,394 | -31,639 |
Net Income | -22,845 | -24,640 | -24,394 | -31,641 |
Net Change In Cash | 5 | 5 | 5 | 37 |
Free Cash Flow | -27,118 | -18,108 | -16,357 | -16,533 |
Cash | 31,474 | 57,128 | 79,019 | 135,158 |
Basic Shares | 71,084 | 70,924 | 70,801 | 58,442 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $426 | $-68 | $4,410 | $8,185 |
Gross Profit | -65,373 | -136 | 3,859 | -25,324 |
EBITDA | -87,935 | -84,402 | -96,533 | -54,154 |
EBIT | -88,412 | -84,902 | -97,085 | -54,452 |
Net Income | -88,447 | -84,713 | -96,171 | -49,044 |
Net Change In Cash | 426 | -68 | 4,410 | 8,185 |
Cost of Revenue | 74,382 | 106,955 | ||
Free Cash Flow | -75,857 | -62,712 | -90,549 | -34,779 |
Cash | 135,117 | 111,097 | 190,300 | 115,917 |
Basic Shares | 53,246 | 46,926 | 41,283 | 25,637 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.32 |
2024-06-30 | -$0.35 |
2024-03-31 | -$0.34 |
2023-12-31 | -$0.33 |
